Stock Scorecard
Stock Summary for Dyne Therapeutics Inc (DYN) - $21.18 as of 11/24/2025 3:16:27 PM EST
Total Score
9 out of 30
Safety Score
44 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for DYN
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for DYN
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for DYN
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for DYN
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for DYN (44 out of 100)
| Stock Price Rating (Max of 10) | 7 |
| Historical Stock Price Rating (Max of 10) | 5 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 3 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 5 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for DYN
Financial Details for DYN
Company Overview |
|
|---|---|
| Ticker | DYN |
| Company Name | Dyne Therapeutics Inc |
| Country | USA |
| Description | Dyne Therapeutics, Inc. is an innovative biotechnology company based in Waltham, Massachusetts, dedicated to revolutionizing the treatment of genetically-driven muscle diseases through its proprietary muscle-targeted delivery platform. The firm is advancing a robust pipeline of therapeutic candidates aimed at addressing significant unmet medical needs in this specialized field. With a strong focus on developing impactful therapies, Dyne Therapeutics is well-positioned to enhance patient outcomes and improve the quality of life for individuals suffering from muscle disorders, making it a compelling investment opportunity within the biotechnology sector. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 21.18 |
| Price 4 Years Ago | 11.89 |
| Last Day Price Updated | 11/24/2025 3:16:27 PM EST |
| Last Day Volume | 2,155,319 |
| Average Daily Volume | 2,846,098 |
| 52-Week High | 31.32 |
| 52-Week Low | 6.36 |
| Last Price to 52 Week Low | 233.02% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 43.52 |
| Sector PE | 86.12 |
| 5-Year Average PE | -4.52 |
| Free Cash Flow Ratio | 5.27 |
| Industry Free Cash Flow Ratio | 13.25 |
| Sector Free Cash Flow Ratio | 27.29 |
| Current Ratio Most Recent Quarter | 13.47 |
| Total Cash Per Share | 4.02 |
| Book Value Per Share Most Recent Quarter | 4.85 |
| Price to Book Ratio | 4.37 |
| Industry Price to Book Ratio | 34.10 |
| Sector Price to Book Ratio | 33.20 |
| Price to Sales Ratio Twelve Trailing Months | 0.00 |
| Industry Price to Sales Ratio Twelve Trailing Months | 31.97 |
| Sector Price to Sales Ratio Twelve Trailing Months | 15.80 |
| Analyst Buy Ratings | 9 |
| Analyst Strong Buy Ratings | 5 |
Share Statistics |
|
| Total Shares Outstanding | 142,825,000 |
| Market Capitalization | 3,025,033,500 |
| Institutional Ownership | 110.53% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -34.54% |
| Reported EPS 12 Trailing Months | -3.62 |
| Reported EPS Past Year | -2.78 |
| Reported EPS Prior Year | -3.35 |
| Net Income Twelve Trailing Months | -423,801,000 |
| Net Income Past Year | -317,418,000 |
| Net Income Prior Year | -235,937,000 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 573,610,000 |
| Total Cash Past Year | 435,449,000 |
| Total Cash Prior Year | 121,626,000 |
| Net Cash Position Most Recent Quarter | 474,463,000 |
| Net Cash Position Past Year | 435,449,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 99,147,000 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 0.87 |
| Total Stockholder Equity Past Year | 629,838,000 |
| Total Stockholder Equity Prior Year | 91,292,000 |
| Total Stockholder Equity Most Recent Quarter | 691,783,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -397,011,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -2.78 |
| Free Cash Flow Past Year | -294,745,000 |
| Free Cash Flow Prior Year | -188,887,000 |
Options |
|
| Put/Call Ratio | 0.13 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.75 |
| MACD Signal | 0.99 |
| 20-Day Bollinger Lower Band | 6.72 |
| 20-Day Bollinger Middle Band | 14.07 |
| 20-Day Bollinger Upper Band | 21.42 |
| Beta | 1.30 |
| RSI | 58.86 |
| 50-Day SMA | 14.22 |
| 150-Day SMA | 18.42 |
| 200-Day SMA | 16.20 |
System |
|
| Modified | 11/24/2025 10:04:06 PM EST |